Supernus Pharmaceuticals Inc (SUPN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Total Assets Chart for Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc (SUPN) total assets for FY2025 were USD 1.5B, a 6.2% change from FY2024. Supernus Pharmaceuticals Inc's total assets grew from USD 77.1M in 2008 to USD 1.5B in 2025 (1783.3% over 17 years). Total assets compound annual growth rate: 5-year CAGR of -0.7%, 10-year CAGR of 22.6%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $2.21B
- Implied Share Price
- $37.88
- Enterprise Value
- $2.19B
- Revenue (TTM)
- $830.44M
- EBITDA
- $110.43M
- Profit Margin
- -13.23%
- Trailing P/E
- —
- Forward P/E
- 20.16
- Price/Book (MRQ)
- 2.45
- Price/Sales (TTM)
- 2.66
- EV/EBITDA
- 51.86
- EV/Revenue
- 2.64
- Dividend Yield
- —
- Book Value
- $17.73
- Free Cash Flow (FY2025)
- $45.99M
- Free Cash Flow Yield
- 2.09%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.